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3Three years after the last global assessment of Amphetamine-Type Stimulants (ATS), the manufacture and trafficking 
of these drugs remains a serious and constantly evolving challenge. The 2011 Global ATS Assessment shines a pow-
erful light on ATS helping governments to better understand this important phenomenon.
Once viewed as purely a cottage industry, ATS manufacture and trafficking has undergone its own industrial revolu-
tion. After cannabis, ATS are the second most widely used drugs across the globe outstripping the use of heroin or 
cocaine. ATS are now manufactured and marketed with organized crime groups involved throughout the production 
and supply chain. 
Until recently, the ATS trade was sometimes ignored in favour of the traditional focus on heroin and cocaine. But 
there is growing recognition that the expansion of the ATS trade and its high profits threaten security, health and 
the welfare of populations across the globe. 
While seizures of heroin, cocaine and cannabis remained largely stable between 2005 and 2009, ATS seizures, 
excluding ecstasy, showed a clear increase over the same period. In South-East Asia, for example, the number of 
methamphetamine pills seized grew significantly: from 32 million in 2008, to 93 million in 2009 and 133 million in 
2010. 
Injecting ATS use is also growing and increasing the risk of blood borne diseases such as HIV/AIDS. In Thailand, 
injecting is the second most common delivery system for ATS, while in New Zealand it is the most commonly injected 
drug. Injecting use is also now commonplace in some countries in Europe. 
In addition to amphetamines and ecstasy, established ATS markets have seen the emergence of so-called analogue 
substances falling outside of international control. Substances such as mephedrone or methylenedioxypyrovalerone 
(MDPV) are sold as ‘bath salts’ or ‘plant food’ and act as substitutes for illicit stimulant drugs such as cocaine or 
ecstasy. 
ATS are attractive to millions of drug users in all regions of the world because they are affordable, convenient to 
the user and often associated with a modern and dynamic lifestyle. Their risks are often underestimated in public 
perception. 
In terms of the overall number of ATS users in the last twelve months, this appears to have stabilised, but there were 
increases in some parts of the world where there were few problems with ATS. 
Such developments make ATS tidal by nature; rising and falling as demand increases and decreases around the 
globe. This also explains why the Assessment shows regions suffering high-tides or low-tides in ATS terms with the 
transition often occurring in extremely short periods of time. Most importantly, the flow of ATS trafficking exploits 
vulnerable states, often weakened by instability and insecurity. 
ATS manufacture has also expanded into new regions and there has been a diversification of the drug’s precursor 
chemicals and manufacturing methods. Additional countries in South-East Asia now report ATS manufacture, as 
well as the growth of interregional trafficking in countries with no previous history of the drug. 
Methamphetamine may also be expanding into Europe with several countries reporting an increase in its use and 
production. Illicit laboratories have been seized in many European countries. There are also signs that the drug may 
be replacing amphetamine in some parts of Europe. 
Once thought to be largely unaffected by the illicit manufacture and trafficking of ATS, West Africa has now been 
drawn into the trade’s orbit. Methamphetamine manufacture has been reported from Nigeria. Since 2008, seizures 
in several East Asian countries —notably Japan and the Republic of Korea—appear to have their origin in West 
Africa. ATS manufacture is also increasingly reported from Central America and South America. 
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data sources and timeframes	–	Unless	indicated	specifically,	data	contained	in	this	report	draw	upon	official	sources	
as	reported	in	the	UNODC	Annual	Reports	Questionnaire	(ARQ)	by	Member	States,	annual	and	technical	reports	of	the	











































































































































Reports	 of	ATS	manufacture	 have	 also	 emerged	 from	 countries	 in	Central	America	 and	 South	America.	 Six	 illicit	 ATS	
laboratories	were	 reported	seized	 in	2009.	However,	as	ATS	data	 from	the	 region	 is	 in	short	 supply,	partly	due	 to	 the	
















South-East	Asia.	 Strong	 increases	 in	amphetamine	 seizures,	mostly	 in	 the	 form	of	Captagon,3	 in	 some	countries,	 e.g.	
Jordan,	the	Syrian	Arab	Republic	and	the	United	Arab	Emirates	might	also	point	to	possible	manufacturing	activity	in	the	









intrinsic characteristics of ats contributing to their attractiveness vis-à-vis 
the traditional plant-based drugs heroin and cocaine:
on the demand side
•• ATS are attractive because they are perceived as enhancing performance and communication and have come to 
embody a modern and fashionable lifestyle (the extent to which ATS are used for occupational or recreational 
purposes depends on the specific substance);
•• ATS can be taken orally. In addition to being ‘convenient’ for the user, the use of pills also avoids injection or 
smoking and the dangers of social stigma associated with these administration routes;
•• ATS are affordable (available on retail markets in single pill units);
•• The recreational use of ATS is generally perceived as not being very harmful, and controllable; public health risks 
of ATS are frequently underestimated in public perception, as well as in the judicial and enforcement areas;
on the supply side
•• ATS are attractive because of high profits: with little initial investment, hugely profitable quantities of drugs can 
be manufactured;
•• ATS can be made readily from a variety of starting materials (precursors) using a variety of synthesis methods. 
When a traditional precursor becomes unavailable, the desired precursor may itself be synthesized from a pre-
precursor chemical;
•• ATS manufacture is not limited to certain geographic locations. It can take place anywhere, be easily camou-
flaged, and be relocated as enforcement pressure increases (e.g. makeshift laboratories set up to supply a single 
order and then dismantled to prevent detection);
•• Because there are no geographical limitations, ATS laboratories can be located close to the areas of consump-
tion, thus minimizing the risk of detection when trafficking end-products across international borders;
•• Awareness of ATS end-products and/or their precursors is still limited in some parts of the world where other 
drugs prevail, thus minimizing the risk for illicit operators and trafficking groups;
•• For operators of small-scale ‘kitchen’ laboratories (typically methamphetamine laboratories), ATS are attractive 
because manufacture does not usually require advanced knowledge of chemistry and can be accomplished by 
anyone from readily available chemicals. 
(Information drawn partly from previous UNODC publications: Understanding clandestine synthetic drugs (2001) and Ecstasy and amphetamines 













nylacetate	 have	 been	 seized	 in	 illicit	 ATS	 laboratories	 in	Mexico.	Another	 substitute	 substance,	 l-phenylacetylcarbinol	
(l-PAC),	a	precursor	of	ephedrine),	was	reported	as	having	been	found	in	illicit	ATS	manufacturing	operations	in	Canada.	
neW ats trafficKinG routes in asia
Over	the	last	few	years,	the	ATS	market	has	moved	from	being	a	cottage-type	industry	(with	many	small-scale	manufac-
turing	operations)	to	more	of	a	cocaine	-	or	heroin	-type	market,	characterized	by	a	higher	level	of	integration	and	involve-
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injection	 are	 also	 reported	 in	 the	Czech	 Republic	 as	well	 as	 Sweden,	 Estonia,	 Finland,	 Latvia,	 Lithuania,	Georgia	 and	
Ukraine.
DecLine anD possiBLe resurGence of ecstasy anD emerGence of ana-




substances	 are	marketed	as	 so-called	 ‘legal	highs’	 and	mimic	 the	effects	of	 taking	 illicit	 stimulant	 substances	 such	as	
ecstasy	 or	 amphetamines.	Widely	 used	 substances	 include	 BZP,	mephedrone	 (4-methylmethcathinone	 (4-MMC))	 and	
MDPV.	The	new	unregulated	synthetic	compounds	appeared	first	in	established	ATS	markets,	particularly	in	Europe,	the	
United	States,	Canada,	Australia	and	New	Zealand	but	have	meanwhile	spread	to	other	markets,	e.g.	Philippines.	





Greater mekong subregion: primary methamphetamine trafficking routes
Source: CCDAC, 2009 
















Expanded trafficking routes (after 2003)
Emerging trafficking routes













could	 affect	 the	 availability	 of	 unregulated	 substances	on	
the	ATS	market.	
Data constraints
Analysing	ATS	markets	 and	 developing	 an	 evidence	 base	
upon	which	 actions	 to	 counter	 the	ATS	 problem	 can	 be	




and	Middle	 East,	 parts	 of	 the	Americas,	 Africa	 and	most	
Pacific	 Island	 states	 and	 territories.	 As	 this	 report	 shows,	
these	are	often	the	very	regions	for	which	there	are	already	
indications	of	a	future	spread	of	the	ATS	problem.	
Irregular	 or	 incomplete	 reporting	 from	Member	 States	 is	
compounded	by	the	varying	quality	of	data	provided.	Spe-
cifically,	and	similar	to	other	drugs,	 information	about	the	




(for	 example,	 China	 and	 India).	 The	 lack	 of	 systematic	
forensic	information	on	the	specific	ATS	substances,	the	actual	precursors	used	and	the	size	and	capacity	of	clandestine	
























The	 international	community	has	recognized,	most	notably	 in	the	1998	UNGASS	Action	Plan on ATS	as	well	as	 in	the	
2008	Political	Declaration	and	Plan	of	Action	on	International	Cooperation	towards	an	Integrated	and	Balanced	Strategy	
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to	Counter	the	World	Drug	Problem,	that	ATS	continue	to	pose	a	serious	and	constantly	evolving	challenge	to	interna-












































seizure	of	nearly	22	million	methamphetamine	pills	 in	February	2010	 in	Lao	People’s	Democratic	Republic,	one	of	 the	
largest	seizures	ever	in	the	region.	In	addition,	increasing	amounts	of	chemicals	and	pharmaceutical	preparations	used	for	





























































* From 2007 onwards, reported prevalence percentage is based on midpoint of range. 
- Not reported. 
Source: UNODC ARQ/DELTA
east and south-east asia: ats laboratories, seizures, and annual prevalence rates (2004-2009)
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Ketamine seizures in east and south-east asia, 
2006-2010
Source: DAINAP
Greater mekong subregion: primary methamphetamine trafficking routes
Source: CCDAC, 2009 





















































Expanded trafficking routes (after 2003)
Emerging trafficking routes



























































2011 GLoBaL ATS ASSESSMENT
myanmar: domestic trafficking routes of  
methamphetamine pills
Source: CCDAC, 2009 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations.
combined methamphetamine pill seizures in china, Lao people’s Democratic republic, myanmar and thailand 
 
Source: DAINAP
myanmar: seizures of ephedrine and  
pseudoephedrine, 1997-2010
*Cold tablets containing pseudoephedrine.  
Source: CCDAC, 2009



































































































































northern	 Thailand	 during	 the	 past	 three	 to	 four	 years	
originated	 from	 the	Myanmar	 part	 of	 the	Golden	 Trian-
gle.7
Only	 two	million	methamphetamine	 pills	were	 seized	 in	
2010,	 compared	 to	 seizures	 of	 nearly	 24	million	 pills	 in	
2009.	Seizures	in	2008	and	2007	amounted	to	1.1	million	
pills	 and	 1.6	million	 pills,	 respectively.8	 The	 significant	
increase	 in	2009	was	 likely	due	to	Government	pressure	
on	ceasefire	groups,	many	of	which	manufacture	ATS,	to	









































myanmar: bottles of ephedrine-containing nasal drops 
seized in special region 1 (Kokang)
Source: CCDAC, 2009
22
2011 GLoBaL ATS ASSESSMENT
of	 the	 tablets	were	 believed	 to	 be	 destined	 for	 illicit	 ATS	
manufacturing	facilities	 in	Myanmar.	Since	2008,	approxi-
mately	 35	million	preparations	 and	192	 kg	of	 bulk	 pseu-









land	 have	 increased	 each	 year	 since	 2007.	 During	 that	
period,	methamphetamine	pill	seizures	rose	from	14	million	
pills	 in	2007	to	22	million	pills	 in	2008,	27	million	pills	 in	
2009	and	nearly	50	million	pills	in	2010.	At	the	same	time,	























































































Number of  seizures
Seizures (kg)
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Greater meKonG suBreGion / ThAILAND
DruG type
neW aDmissions aLL aDmissions
maLe femaLe totaL maLe femaLe totaL
Methamphetamine pills 73,530 6,940 80,470 89,822 8,225 98,047
Crystalline methamphetamine 939 691 1,630 1,214 805 2,019
Ecstasy-type (MDMA) 83 69 152 102 82 184
Cannabis 5,559 66 5,625 6,664 77 6,741
Cocaine 7 5 12 11 7 18
heroin 500 18 518 1,276 62 1,338
Inhalants 3,064 88 3,152 4,037 115 4,152
Ketamine 3 5 8 6 5 11
Kratom 1,904 52 1,956 2,136 53 2,189
Opium 713 205 918 1,451 436 1,887
total 86,302 8,139 94,441 106,719 9,867 116,586
Source: DAINAP
thailand: drug treatment admissions, 2010
DruG type
neW aDmissions aLL aDmissions
maLe femaLe totaL maLe femaLe totaL
Methamphetamine pills 64,690 6,945 71,635 78,620 8,196 86,816
Crystalline methamphetamine 350 351 701 435 408 843
Ecstasy-type (MDMA) 155 96 251 181 103 284
Cannabis 6,610 89 6,699 7,794 104 7,898
Cocaine 10 2 12 15 4 19
heroin 513 25 538 1,232 62 1,294
Inhalants 4,466 160 4,626 5,517 197 5,714
Ketamine 10 1 11 11 1 12
Kratom 1,385 35 1,420 1,527 34 1,561
Opium 795 261 1,056 1,482 485 1,967
total 78,984 7,965 86,949 96,814 9,594 106,408
Source: DAINAP
thailand: drug treatment admissions, 2009
DruG type  
(measurement)













36,252 13,820,000 73,014 14,340,000 113,877 22,115,911 105,916 26,640,206 125,195 48,587,522
Crystalline metham-
phetamine (kg)
734 92.2 1,258 47.4 1,960 52.9 2,507 209 6,602 733.02
Ecstasy-type (MDMA) 
(pills)
300 26,656 295 315,444 460 486,533* 296 58,024 147 16,081
Ketamine (kg) 95 22.7 63 2.8 140 18.1 130 18.9 154 172.03
* 2008 pill seizures converted into kg equivalents at 1 pill = 300 mg.
Source: DAINAP
thailand: ats and ketamine seizures, 2006-2010
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phetamine	 pill	 seizures	 in	 other	 countries	 in	 the	Greater	Mekong	 Subregion,	 the	 Lao	 People’s	 Democratic	 Republic	
reported	a	more	than	four-fold	rise	in	pill	seizures	from	84	cases	in	2007	to	194	cases	in	2008	and	357	cases	in	2009.	In	









lic	which	were	 previously	 dominated	 by	 opium	use.	 In	 2005,	 government	 authorities	 in	 the	 Lao	 People’s	Democratic	








resenting	a	considerable	burden	on	the	 limited	 law	enforcement,	 judicial,	prison	and	health	care	 resources	of	 the	Lao	
People’s	Democratic	Republic.	
Lao people’s Democratic republic: seizures of methamphetamine pills, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Methamphetamine pills No. of pills 1,755,989 1,272,815 1,227,205 2,335,330 24,530,177
Source: DAINAP
number of patients at somsanga treatment and rehabilitation center, 2003-2009 
DruG type 2003 2004 2005 2006 2007 2008 2009
Total no. of patients 1,714 2,658 1,376 1,177 1,894 1,682 1,964





















kg	of	ephedra	grass,	13	kg	of	ephedra	seeds	as	well	as	1,373	kg	of	unknown	 liquids.34	 In	 the	same	year,	Cambodia	
reported	its	first	seizure	of	an	extraction	site	for	ephedrine,	in	the	Kompong	Cham	province,	which	was	utilizing	ephedra	
grass	suspected	to	have	been	trafficked	from	northern	China.35	
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viet nam






difficult	 to	 assess	 due	 to	 the	 limited	 information	 available.	 The	 large	 number	 of	 chemical	wholesalers,	 suppliers	 and	

































DruG type measurement 2005 2006 2007 2008 2009 2010
Methamphetamine pills No. of pills 351,651 428,553 420,287 116,772 137,249 82,746
Crystalline methamphetamine kg 2 16.2 6.75 1.9* 4.6 9.9
Ecstasy-type (MDMA) No. of pills – – 300 33 3,352 1,056
Ketamine kg – – – 495** 1.14 0.001
* Plus 15 'small packs' undefined weight. ** Small bottles, undefined weight.
Source: DAINAP
cambodia: seizures of selected drugs, 2005-2010
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Greater meKonG suBreGion / ChINA
accounted	 for	 roughly	 40%	of	 all	 the	methamphetamine	




Despite	 the	 impact	of	 the	 spillover	of	Myanmar-manufac-
tured	methamphetamine	pills	 in	2009,	aggregate	seizures	
of	methamphetamine	 (in	 both	 pill	 and	 crystalline	 forms)	
during	the	year	(6.6	mt)	remained	within	the	range	of	the	
6.1	mt	and	6.8	mt	seized	each	year	during	the	2005-2009	





increased	 significantly	 since	 2005	 and	 a	 considerable	
number	 of	 ketamine	manufacturing	 facilities	 have	 also	
been	 dismantled.	 China	 reports	 the	 highest	 seizures	 of	
ketamine	in	the	world,	having	reported	annual	seizures	of	
about	5.4	mt	for	the	past	four	years.	The	5.3	mt	of	keta-













Hong Kong (special administrative region of china)
Most	clandestine	ATS	manufacture	in	Hong	Kong,	China	has	consisted	of	ecstasy-type	tableting	and	repackaging	opera-
tions.60	However,	Hong	Kong	police	 reported	 the	 seizure	of	 two	small-scale	 clandestine	crystalline	methamphetamine	
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Ketamine	users	account	 for	nearly	38%	of	all	drug	users	 in	Hong	Kong,	China.	Among	drug	users	below	 the	age	of	
21	an	estimated	84%	have	used	ketamine.63	Previously,	most	of	 the	ketamine	 trafficked	 into	Hong	Kong,	China	was	
trafficked	in	small	quantities	across	the	land	boundary	with	mainland	China,	by	a	large	number	of	traffickers.	By	2005,	
large,	multi-kilo	quantities	of	ketamine	originating	in	India	and	transported	into	Hong	Kong,	China	via	South-East	Asia	
were	 also	 detected.	 There	 are	 indications	 that	 criminal	 syndicates	 are	 increasingly	 procuring	 the	 precursor	 chemical	












































nortH-east asia / REPUBLIC OF KOREA
ized	crime	members.	As	with	many	countries	in	Asia,	many	
nationals	 from	 the	 Islamic	 Republic	 of	 Iran	 have	 been	
arrested	in	Japan	in	methamphetamine-related	cases	in	the	
past	 few	 years,	 including	 85	 in	 2009	 and	 50	 in	 2010.72	
Much	of	the	methamphetamine	trafficked	into	Japan	con-
sists	 of	 small	 packages	 carried	 by	 couriers	who	 enter	 the	
country	by	air	 and	 sea.	However,	 sophisticated	 trafficking	




seized	 each	 year,	 slightly	 less	 than	 the	 amounts	 seized	 in	
the	early	part	of	the	decade.73




not	 been	 reported	 in	 Japan.	 Use	 of	 ecstasy	 pills	 is	more	
common	 but	 declining	 numbers	 of	 arrests	 and	 declining	
seizures	of	the	drug	over	the	past	several	years	suggest	that	
use	has	gone	down.74	During	the	past	decade	about	80%	
of	 all	 drug-related	 arrests	 in	 the	 country	 have	 involved	
methamphetamine.	 In	 addition,	more	 than	 50%	 of	 all	
drug-related	treatment	demand	from	clients	 in	psychiatric	













DruG type 2006 2007 2008 2009 2010
Methamphetamine 11,606 12,009 11,025 11,655 11,999
Ecstasy-type (MDMA) 370 296 281 107 62
Source: JNPA, 2011
Japan: ats-related arrests, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Crystalline methamphetamine Kg 126.8 339.3 397.5 356.3* 302.3
Ecstasy-type (MDMA) and 
other synthetic drugs
Pills 186,226 1,233,883 217,172 85,688 17,326
* UNODC, 2010d.
Source: JNPA, 2011
Japan: ats seizures, 2006-2010




































12.8	million	 pharmaceutical	 preparations	 containing	 pseudoephedrine,	 originating	 from	 the	 Republic	 of	 Korea,	were	
seized	in	Cambodia	after	having	been	trafficked	across	the	land	border	with	Thailand.	However,	it	is	unclear	whether	these	
products	were	intended	for	direct	use	or	for	use	in	illicit	methamphetamine	manufacture.81
republic of Korea: ats-related arrests, 2006-2010
DruG type 2006 2007 2008 2009 2010
ATS 6,006 8,521 7,457 7,965 6,771
total 7,709 10,649 9,898 11,875 9,732
Source: SPO, 2011
republic of Korea: ats seizures, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010
Crystalline methamphetamine kg 21.5 23.7 25.5 15.2 11.8
Methamphetamine pills No. of pills 0 196 151 1 5
Ecstasy -type (MDMA) No. of pills 356 18,323 714 894 486
Source: SPO, 2011
retail prices of crystalline methamphetamine in the republic of Korea, 2006-2010
DruG type measurement 2006 2007 2008 2009 2010






63%	 of	 persons	 receiving	 drug	 treatment.	 Since	 2008,	
about	 two-thirds	of	all	drug-related	arrests	 in	 the	country	
have	been	related	to	crystalline	methamphetamine.	There	is	
no	 reported	 use	 of	methamphetamine	 pills	 in	 the	 Philip-
pines.	
In	major	cities	the	use	of	ecstasy	 is	becoming	 increasingly	
popular	 among	 young	 nightclub	 goers.	 Ecstasy	 use,	
however,	 remains	 limited	 due	 to	 the	 high	 price	 and	 low	
availability.	 The	 use	 of	 synthetic	 substances,	 such	 as	





















nortH-east asia / PhILIPPINES
Illicit	crystalline	methamphetamine	manufacture	in	the	Phil-
ippines	was	 first	 reported	 in	1996,	 and	 in	1997,	 the	 first	
industrial-scale	clandestine	manufacturing	 facility	was	dis-
mantled.	 From	 2002	 to	 2010,	 a	 total	 of	 72	 clandestine	
crystalline	methamphetamine	laboratories	were	dismantled	
by	drug	law	enforcement	authorities.83	Over	the	past	few	
years,	methamphetamine	manufacture	 has	 shifted	 from	
large	and	medium-sized	 facilities	 to	 smaller	 ‘kitchen	 type’	
laboratories	in	metropolitan	areas	and	has	been	character-
ized	by	the	manufacture	of	increasingly	higher	purity	meth-





nesia	 and	 Thailand	 as	 well	 as	 to	 countries	 outside	 the	
region.	 The	 Philippines	Drug	Enforcement	Agency	 reports	
that	nine	transnational	criminal	groups	and	85	local	groups	
are	 involved	 in	drug	manufacturing	and	 trafficking	 in	 the	






primary ats trafficking routes for the philippines
Source: PDEA, 2010 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United 
Nations. Lines represent origin and intended destination, not necessarily the exact route used, and may include completed or stopped trafficking 
attempts.












Primary international trafficking routes for crystalline 
methamphetamine manufactured in the Philippines
ATS manufactured in China are trafficked directly to
the Philippines or through Thailand











































source	 of	methamphetamine	pills	 trafficked	 into	Malaysia	 and	 is	 also	 a	 source	 of	 some	 crystalline	methamphetamine	


































soutH asia / INDIA
Although	the	illicit	manufacture	of	large	quantities	of	ATS	has	partially	eliminated	the	need	for	the	trafficking	of	ATS	into	









South	Asia	 is	 located	at	the	crossroads	of	drug	supply	between	the	sources	 in	South-East	Asia	(formerly	known	as	the	
‘Golden	Triangle’)	and	West	Asia.	Traditionally,	the	subregion	has	been	affected	by	the	illicit	manufacture,	trafficking	and	
use	of	drugs,	mostly	opiates.	Over	the	past	few	years,	however,	South	Asia	has	become	an	area	for	illicit	ATS	manufacture	












doephedrine,	 the	chemicals	 frequently	used	 in	 the	 illicit	manufacture	of	methamphetamine.	The	first	known	 illicit	ATS	
laboratory	was	detected	and	dismantled	in	Kolkata	in	May	2003.	In	2004,	a	laboratory	was	seized	in	Hyderabad	(south-
eastern	 India),	 and	another	 laboratory	was	 seized	 in	Gurgaon	 (northern	 India)	 in	2006.	 Several	 additional	 facilities	or	













































pharmaceutical	 industry	 is	developing	fast	and	the	absence	of	 legislative	controls	on	precursor	chemicals	 increases	the	
country's	vulnerability	to	traffickers.
centraL asia anD countries of tHe caucasus
The	amount	of	information	available	from	the	Central	Asian	countries	of	the	Caucasus	related	to	ATS	is	sparse,	but	Gov-
ernment	reports	suggest	that	ATS	expansion	may	be	occurring,	albeit	from	very	low	levels.	The	subregion	has	experienced	
some	 small-scale	 illicit	manufacture	 of	methcathinone,	which	was	made	 from	 the	 naturally	 occurring	 ephedra	 plant.	
Georgia	reported	its	first	methamphetamine	seizure	in	2006	(2.42	kg),	while	Kazakhstan	reported	a	seizure	of	3.6	kg	of	









































































































* From 2007 onwards, reported prevalence percentage is based on midpoint of range. 
- Not reported. 
Source: UNODC ARQ/DELTA
oceania: ats laboratories, seizures, and annual prevalence rates (2005-2009)
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The number of extraction laboratories for ephedrine and pseudoephedrine increased from 38 in 2008-2009 to 44 in 
2009-2010. 
The most common method of manufacture detected in ATS clandestine laboratories in Australia is the hypophosphorous 
method, followed by the Birch method, the red phosphorous method and the P-2-P method. With the exception of the 
P-2-P method, all other methods experienced a substantial increase. The number of seized laboratories using the red 
phosphorus method more than doubled, from 16 in 2008–09 to 51 in 2009–10.
The number of ecstasy laboratories decreased from 19 in 2008–09 to 17 in 2009–10. By far, the most laboratories are 
reported from New South Wales (12), followed by Queensland (3) and South Australia (2). 
Australian law enforcement authorities also seized manufacturing equipment, notably pill presses. On 1 March 2010, a 
new regulation on the prohibition of importation of pill presses came into force and a total of 57 pill presses were seized 
in 2009–10, compared to 26 in 2008–09. Most pill presses were seized in New South Wales (30). 
The number of ATS arrests decreased by 15% nationally, from 16,000 in 2008-09 to 14,000 in 2009–10 but still remain 
historically high. Compared to 2005–06, arrests are 40% higher. User offences accounted for 71% of the total ATS arrests 
in 2009–10. The percentage of detainees testing positive for amphetamines has been decreasing since 2006. In 2008, it 
was lower than at any point in time since 2000.
The number of ATS (excluding ecstasy) seizures increased by 71% in 2009–10, from 391 in 2008–09 to 672. The highest 
number of seizures reported in the last five years was 743 in 2006–07.  
At 67kg, seizures of amphetamines declined significantly in 2009-2010, compared to 2008-2009 when 346 kg were 
seized. Of the 67 kg of total amphetamines seized, slightly more than half (35.8 kg) was in the form of crystalline meth-
amphetamine. In 2009-2010, most of the seized amphetamines shipments came from Spain. South Africa was another 
important point of embarkation, accounting for 28% of seizures totalling more than 500 grams. China, including Hong 
Kong, was another embarkation point. 
Ecstasy seizures have hit a five-year low in Australia, in terms of both seizures and weight. About 6 kg of ecstasy were 
detected at the Australian border in 2009-2010, half the amount seized in 2008-2009 (12 kg). It should be noted that all 
Australia: number of dismantled ATS laboratories
Source: ACC, 2011 
Note: Data are based on financial year (1 July-30 June).
Australia: adult detainees who tested positive for  
amphetamines (%), 2003-2008
Source: UNODC ARQ/DELTA 
Note: Data are based on financial year (1 July-30 June).































































































































Seizures	 of	 precursors	 (ephedrine,	 ephedra,	 P-2-P,	 pheny-
lacetic	Acid,	phenylpropanolamine/norephedrine	and	pseu-
doephedrine)	used	in	illicit	ATS	manufacture	have	shown	a	





2007,	 20	 to	 29	 year	 olds	 have	 consistently	 reported	 the	
highest	 proportion	 of	 amphetamine-group	 users	 in	 the	
population	 since	 1998.	 Lifetime	 prevalence	 in	 this	 age	
group	was	 16%	 (470,000),	 last	 12	months	 7.3%,	 and	










australia: ats seizures (excluding ecstasy) by the aus-
tralian customs Border and protection service, 2005-
2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 
Note: Data are based on financial year (1 July-30 June).
australia: total weight and number of seizures  
of crystalline methamphetamine detected by the  
australian customs Border and protection service, 
2005-2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 
Note: Data are based on financial year (1 July-30 June).
australia: total weight and number of seizures of 
ecstasy detected by the australian customs Border 
and protection service, 2005-2010
Source: Australian Customs Border and Protection Service, 2010; 
Australian Customs Border and Protection Service, 2008 






























































































































































































2011 GLOBAL ATS ASSESSMENT
amphetamine powder (speed), base and ice as easy or very 
easy to obtain. Participants purchased all forms of metham-
phetamine from a variety of sources, most commonly 
through friends and known dealers. 
The price2 for a gram of all forms of methamphetamine in 
2010 remained relatively stable compared to 2009. The 
average national price for speed and base increased from 
$250 to $300 and from $200 to $250 respectively. The 
price for crystalline methamphetamine remained stable 
compared to 2009 ($400).
During 2009–10, the median purity ranged from 4.4% in 
Tasmania to 17% in Western Australia. Western Australia 
has continuously recorded high purities in comparison to 
other jurisdictions over the past decade. The median purity 
of methamphetamine within Australia has been declining 
since 2006-07.
Ecstasy is considered as ‘easy’ or ‘very easy’ to obtain by 
74% of regular ecstasy users. Significantly more partici-
pants in 2010 reported ecstasy to be difficult to very diffi-
cult to obtain compared to 2009 results (26% in 2010, 
12% in 2009). Most jurisdictions reported the availability 
had remained stable.
The median price for a pill of ecstasy ranged from $23 in 
2 A degree of caution should be exercised when considering these figures, 
as fewer than 10 participants in each jurisdiction reported recent purchase 
of different forms of methamphetamine.
New Zealand: dismantled ATS laboratories,  
2000-2010
*2011 figures are for January to end March only. 























































New Zealand: ecstasy pills seized, 2000-2010



























































New Zealand: methamphetamine seizures, 2000-2010
*2011 figures are for January to end March only. 





































































Number of  seizures
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South Australia to $35 in Western Australia. That is a slight increase compared to the price of $20 reported from most 
jurisdictions in 2009.
In 2009-10, the median purity of ecstasy-group substances ranged from 6.8% in South Australia to 23% in Western 
Australia. This is the greatest range recorded since 2000–01. All jurisdictions reported decreases in the median purity, 
apart from Western Australia which has remained relatively stable.
New Zealand
ATS manufacture in New Zealand is primarily related to methamphetamine (locally known as ‘P’) for domestic consump-
tion. Methamphetamine is illegally manufactured mainly from imported pharmaceutical preparations containing ephe-
drine and pseudoephedrine (usually Contac NT from China). Domestic outlaw motorcycle gangs are heavily involved in 
the manufacture and distribution. There are also indicators of possible Vietnamese involvement in the manufacture of 
methamphetamine.
The number of dismantled clandestine ATS laboratories remains relatively stable. In 2010, 130 ATS laboratories were 
discovered. Most of these laboratories were manufacturing methamphetamine or were pseudoephedrine extraction labo-
ratories. One ‘combined ATS’ laboratory was involved in the manufacture of methamphetamine and possibly ecstasy. This 
laboratory was allegedly established to meet local demand for ecstasy. The laboratory was using a pill press to produce 
ecstasy pills. There are currently no legislative or regulatory controls on the importation, possession, and use of pill presses 
in New Zealand.
All laboratories were using ephedrine or pseudoephedrine as the main precursor. The reported yield for both was 50%.
The majority of laboratories continue to be located on private premises on the Upper North Island. The shortage of ephe-
drine and pseudoephedrine has forced some manufacturers to extract ephedrine from the ephedra plant. A laboratory 
extracting ephedrine/pseudoephedrine from the ephedra plant was seized in July 2010.
For 2010, New Zealand reported seizures of 30.4 kg of methamphetamine, a 50% increase compared to 2009. More 
than half of this amount (19.5 kg) was seized at the border, mainly in the form of internal concealments and mail inter-
cepts. Seizures of amphetamine remain relatively small. In 2010, only 0.5 kg of amphetamine were reported seized. 
Primary embarkation points for detections of methamphetamine were Hong Kong, China, China, Indonesia and Australia. 
For amphetamine, the primary embarkation points were Thailand, China and the USA.
The median price for a gram of methamphetamine remains at the same level for the third year in a row (NZ$ 700). The 
mean price for a gram, however, has reportedly increased from NZ$ 738 to NZ$ 780 for a gram.3 
The reported price for amphetamine powder was NZ$ 30 per point (0.1g) and for methamphetamine in powder/crystal 
form NZ$ 780 per gram. 
The purity of methamphetamine in powder/crystal form remains stable at 74%. Methylsulfonylmethane (MSM)4 is the 
usual diluent for methamphetamine in New Zealand.
Thirty-four % of frequent drug users reported that methamphetamine was ‘very easy’ to obtain whereas 2 % reported 
that it was very difficult.
In 2010, New Zealand authorities seized 45,109 ecstasy pills. That is an almost three-fold increase compared to 2009 
when 15,477 pills were seized. The purity of the ecstasy pills remains low. The analyses in the majority of the cases iden-
tified the pills as containing either very little or no MDMA. Pills sold as ecstasy often contain substances like mephedrone, 
ketamine, 4-MEC, BZP, TFMPP, caffeine, Bk-MBDB (butylone), methenamine, methylone and cathinone. 
The price for one ecstasy pill ranges from NZ$ 40 to NZ$ 70 and remained stable compared to 2009. Frequent drug users 
reported the purity of ecstasy to be decreasing compared to 2006 and 2007. The availability of ecstasy was reported  as 
being ‘stable’/ ‘more difficult’ to obtain over the past six months in 2009.
The number of seizures of ephedrine and pseudoephedrine by New Zealand Customs has increased significantly since 
2004. Seizures peaked in 2009, when almost 5.4 million pills (1,203 kg) were seized. In 2010, the number of seized 
precursors dropped by 20% to 4.3 (967 kg). Preliminary data for 2011 shows that seized quantities continue to decline 
in 2011. Asian organized crime groups are predominant in trafficking of ephedrine, pseudoephedrine, and metham-
phetamine.
3 SHORE, 2010. 
4 MSM is often sold as a dietary supplement.
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Methamphetamine-related	convictions	have	been	on	 the	 rise	 since	2004	when	1,167	people	were	convicted.	 In	2009,	
there	were	2,435	convictions	compared	to	2,058	in	2008.










enforcement	capacity	and	a	multitude	of	small	 islands	 increase	the	vulnerability.	 In	addition,	there	 is	a	growing	risk	of	
drug	crimes	from	returning	deportees	with	links	to	criminal	organizations.	
new Zealand: border seizures of ephedrine and  
pseudoephedrine 2004-2010
*2011 figures are for January to end March only. 
Source: New Zealand, 2011
new Zealand: annual prevalence rate of ampheta-












































































































































reGion / COUNTRyoceania 
ATS	 awareness	 is	 low	 and	 very	 few	drug	monitoring	 sys-
tems	exist	in	the	region.	Information	related	to	ATS	manu-
facture,	trafficking	and	use	in	the	Pacific	Island	States	and	






to	 the	 1988	Convention,	 seven	 are	 located	 in	Oceania.	
Most	 Pacific	 Island	 States	 and	 territories	 do	 not	 submit	
ARQs,	none	were	submitted	for	2009.
There	 have	 been	 reports	 of	 kitchen-scale	methampheta-
mine	laboratories	seized	in	Guam	and	there	are	indicators	
that	manufacture	may	be	 spreading	 to	other	 islands.	 The	
most	significant	manufacturing	case	so	far	was	reported	in	
Fiji	 in	 2004.	 It	 involved	 an	 industrial-scale	methampheta-
mine	 laboratory.	 The	 laboratory	was	 operated	 by	 Asian	
organized	 crime	 groups	 and	 purportedly	 contained	 700	
litres	of	liquid	methamphetamine,	5	kg	of	finished	crystal-
line	methamphetamine	 and	 enough	 precursors,	 including	
thionyl	 chloride,	 on	 site	 for	 the	manufacture	 of	 an	 addi-
tional	 1	mt	 of	methamphetamine.	 Production	 cycle	 esti-
mates	for	this	laboratory	were	between	500	and	1,000	kg	
of	 crystalline	methamphetamine	per	week,	making	 it	one	
of	 the	 largest	 laboratories	 ever	 seized.	 There	 have	 been	




















new Zealand: methamphetamine-related convictions, 
2004-2009































large	 seizures	 in	 the	 region	 remaining	unidentified.	The	absence	of	manufacture	 reports	 is	 inconsistent	with	both	 the	
quantity	of	seizures	and	the	availability	of	key	ATS	precursors	in	the	region.
Historically,	 the	Near	and	Middle	East/South-West	Asia	has	served	as	a	corridor	 for	 trafficking	drugs	 from	eastern	and	
southern	Asia	to	illicit	drug	markets	in	Europe.	For	ATS,	however,	recent	trends	indicate	a	reversal	of	traditional	trafficking	
trends	in	some	areas.	For	example,	whereas,	up	to	2007-2008,	methamphetamine	was	trafficked	to	the	Islamic	Republic	


















































































* From 2007 onwards, reported prevalence percentage is based on midpoint of range. ** No estimate could be calculated due to lack of data.  
- Not reported.
Source: UNODC ARQ/Delta
near and middle east/south-West asia: ats laboratories, seizures and annual prevalence rates (2005-2009) 
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near and middle east/south-West asia: annual legitimate requirements for pseudoephedrine, 2006-2010*
*Where years are missing, it indicates that no requirements were reported to INCB by countries that year. 
Source: INCB – Annual legitimate requirements reported by Governments for ephedrine, pseudoephedrine, 3,4 methylenedioxyphenyl-2- 
propanone, 1-phenyl-2-propanone and their preparations (Kilograms)






























2006 5,000 0 0 0 1,400 200
2007 40,000 50,000 10,000 18,000 1,400 200
2008 42,000 50,000 48,000 35,000 1,400 200
2009 55,000 50,000 48,000 20,000 12,000 2,000








pakistan: reported annual legitimate requirements 
for ephedrine and pseudoephedrine, 2006-2010
* No requirements reported.
Source: INCB 2009b, 2010b and 2011b
Global annual legitimate requirement for p-2-p 
reported by Governments
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For	ephedrine,	Pakistan	currently	reports	the	fourth	highest	
legitimate	 requirement	 for	 ephedrine	 in	 the	 world	
(22,000kg);	behind	China,	USA	and	the	Republic	of	Korea.	
Countries	with	 such	 high	 legitimate	 requirements	 can	 be	
attractive	targets	for	precursor	diversion.	
For	P-2-P,	 Jordan	has	 reported	 the	world’s	highest	annual	




(INCB)	 has	 pointed	 out	 that	 the	 volume	 represents	 a	 sig-
nificant	risk	of	diversion	into	illicit	Captagon	manufacture,	




Near	 and	Middle	 East/South-West	 Asia	 have	more	 than	
doubled	since	2005,	 from	11.2	mt	 in	2005	to	25.6	mt	 in	
2009;	 representing	 over	 a	 third	 of	 global	ATS	 seizures	 in	
2009.	Most	 seizures	 concern	 counterfeit	 Captagon	 pills,	
believed	to	contain	amphetamine	as	the	principal	psycho-
tropic	ingredient.3	The	three	countries	reporting	the	highest	
seizures	 are	 Saudi	 Arabia,	 Jordan	 and	 the	 Syrian	 Arab	
Republic.	 At	 24.8	mt,	 total	 seizures	 of	 amphetamine	 in	
2009	from	the	region	constituted	75%	of	global	ampheta-
mine	seizures,	up	from	63%	in	2008.	
The	 origin	 of	 the	 amphetamine	 sold	 as	Captagon	 in	 the	
region	 is	unknown.	Traditionally,	 the	substance	was	believed	to	have	been	manufactured	 illicitly	 in	South-East	Europe,	
notably	Bulgaria,	and	trafficked	to	the	region,	often	transiting	Turkey	by	air	or	sea.	Some	countries	in	the	region,	e.g.	the	
Syrian	Arab	Republic	and	Jordan,	have	named	Turkey	as	a	source.	A	recent	report	by	the	Turkish	National	Police	concluded	
that	 criminal	 organizations	 have	 shifted	Captagon	manufacture	 to	 the	 Syrian	Arab	 Republic.4	 This	 shift	which	would	
appear	to	be	consistent	with	the	significant	decline	in	the	amount	of	seizures	in	Turkey,	which	have	fallen	from	almost	
20	million	pills	in	2006	to	2.8	million	pills	in	2009.5	




















Jordan: reported annual legitimate requirement for 
phenyl-2-propanone (p-2-p)
Source: INCB – Annual legitimate requirements reported by Govern-
ments for ephedrine, pseudoephedrine, 3,4 methylenedioxyphenyl-
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total ats seizures in the near and middle east, 
2005-2009
Source: UNODC ARQ/DELTA
Distribution of amphetamine seizures in the  



















































israel: rates of ecstasy use in the last year among 
12-40 year olds: comparison of surveys
*Latest survey 18-40 year olds (2008) 12-18 year olds (2009).
Source: Bar-hamburger et al., 2009
israel: rates of ecstasy and cathinone (hagigat) use in 
the last year (12-18 year olds): comparison of surveys
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mine,	 specifically	 Captagon,	 trafficked	 on	 their	 territory.	
Following	a	 significant	 increase	 in	 recorded	 seizures	 since	
2003,	seizures	have	shown	the	first	signs	of	stabilization	at	
an	average	of	13.2	mt	since	2006.	In	2009,	seizures	made	
in	 Saudi	 Arabia	 constituted	 about	 one	 third	 of	 global	
amphetamine	 seizures	 (33	mt)	 and	 almost	 one	 fifth	 of	
global	ATS	 seizures	 (71	mt).	 The	 largest	 single	 seizure	 of	
amphetamine	 in	 2009	 (2.5	mt)	was	made	 at	 the	 border	
with	Jordan.	Saudi	Arabia	also	reports	seizures	of	metham-
phetamine,	with	145	kg	being	seized	in	2009.
Information	 on	ATS	use	 is	 hard	 to	 come	by	 but	 scientific	
research	suggests	that	72.8	percent	of	patients	treated	for	
drug	 problems	 in	 Saudi	Arabia	 are	 addicted	 to	 ampheta-
mines.7	Captagon	and	other	amphetamines	are	reportedly	
used	mainly	 by	 students,	 drivers,	 and	 employees	 seeking	
prolonged	 energy.	 The	 extremely	 high	 level	 of	 seizures	 is	




ATS	 seizures	 in	 the	 Syrian	Arab	 Republic	 have	 increased	
more	 than	 six-fold	 since	2005.	 Seizures	 of	 amphetamine,	
mostly	 in	 the	 form	 of	 Captagon	 pills,	 almost	 doubled	
between	2008	and	2009	to	reach	3.7mt	(22	million	pills).	
Government	 reports	 to	UNODC	 associate	 the	 increase	 in	
trafficking	with	 large	 demand	 for	 the	 drug	 and	 attribute	







(29	million	 pills).	 Preliminary	 reports	 for	 2010,	 however,	
indicate	 a	 substantial	 decrease	 in	 seizures.	 The	 increasing	





saudi arabia: seizures of ats, 2005-2009





































syrian arab republic and Jordan:  
seizures of captagon pills, 2005-2009



























Syrian Arab Republic Jordan
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near and middle east/south-West asia: ats seizures, 2005 - 2009
Source: UNODC ARQ/ DELTA
islamic republic of iran










as	a	country	of	origin	 for	methamphetamine	 in	2009.	Government	authorities	have	 reported	further	strengthening	of	








































Saudi Arabia 7.9 12.3 13.9 12.8 13.6
Jordan 1.9 1.9 1.8 2.4 4.9
Syrian Arab Republic 0.6 1.6 2.1 2.1 3.8
Islamic Republic of Iran 0.0 0.0 0.0 1.5 1.5
Yemen 0.0 0.1 2.3 0.9
2005 2006 2007 2008 2009
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Qatar’s	Drug	Combating	Department	(DCD)	arrested	members	of	an	international	criminal	network	engaged	in	drug	traf-




















of	 seized	 laboratories	 reported	 to	UNODC	 from	 the	 region	 since	 2003.	 The	 drop	 is	 largely	 due	 to	 the	 decline	 in	 the	
reported	number	of	methamphetamine	laboratories	dismantled	between	2008	and	2009.	
Europe,	 notably	West	 and	Central	 Europe,	 continues	 to	 be	 an	 important	market	 for	 amphetamine,	 in	 terms	 of	 both	







The	 countries	 of	 origin	 of	 amphetamine	most	 frequently	mentioned	 by	 national	 authorities	 are	 the	Netherlands	 and	
Poland,	while	the	most	frequently	mentioned	destinations	are	Germany,	the	United	Kingdom	and	the	Scandinavian	coun-
tries.	





































































*From 2007 onwards, reported prevalence percentage is based on midpoint of range.
Source: UNODC ARQ/DELTA
europe: ats laboratories, seizures, and annual prevalence rates (2005-2009)
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senting	 a	 significant	 departure	 from	previous	 years	when	
the	seizure	of	ecstasy-group	substances	made	up	a	substan-
tial	 proportion	 of	 seizures.3	 This	 was	 due	 to	 the	 sharp	
decline	in	the	seizures	of	ecstasy-group	substances	reported	
to	 UNODC	 since	 2007	which	 contributed	 to	 the	 overall	
reduction	 in	 total	ATS	 seizures	 in	 the	 region	 in	2008	and	
2009.	Ecstasy-group	 substances	 in	 the	EU	continue	 to	be	
sourced	 almost	 exclusively	 from	 the	 Netherlands	 and	
Belgium,4	with	the	Netherlands	being	the	most	frequently	
mentioned	country	of	origin	for	ecstasy	by	European	coun-
tries.	 Reports	 of	 both	 the	 seizures	 of	 ecstasy-group	 sub-
stances	and	 the	numbers	of	 laboratories	dismantled	have	
been	 largely	 in	 decline	 since	 2005,	with	 only	 one	 illicit	
ecstasy	 laboratory	being	reported	 in	2009	by	Belgium	–	a	
sign	that	manufacture	of	the	drug	formerly	concentrated	in	
Europe	has	 started	 to	 shift	 to	other	 regions	of	 the	world	
such	as	Australia	and	Indonesia.5	





europe: seizures of illicit ats laboratories, 2001-2009
Source: UNODC ARQ/DELTA








































































































































Reports	 of	 illicit	methamphetamine	manufacture	 in	 the	 form	of	mostly	 small-scale	 laboratories	 continued	 to	 emerge	
mainly	from	the	Czech	Republic	and,	to	a	lesser	extent,	Slovakia	and	Germany.	In	comparison	to	most	other	regions	of	
the	world,	illicit	manufacture	of	methamphetamine	is	fairly	low.	However,	Austria,	Belarus,	Lithuania,	Netherlands,	Poland	
and	Portugal	have	all	 recently	 reported	first	 time	seizures	of	methamphetamine	 laboratories	which	 indicates	 that	 illicit	
methamphetamine	activity	may	be	spreading	through	the	region.	
The	European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	(EMCDDA)	and	Europol	point	to	a	possible	replacement	
of	amphetamine	by	methamphetamine	on	 the	 illicit	market	especially	 in	 some	Nordic	and	Baltic	 countries.7	EMCDDA	













amphetamine	users	 is	relatively	small	 in	the	majority	of	European	countries	and	trends	 in	amphetamine	users	entering	
treatment	between	2003	and	2008	have	 remained	broadly	 stable	 in	most	countries.12	 In	Sweden,	Finland	and	Latvia,	
treatment	for	use	of	amphetamine	as	the	primary	drug	is	proportionally	much	higher.13	Along	with	the	Czech	Republic,	
Estonia	and	Lithuania,	 these	countries	have	also	 reported	high	 rates	of	 injecting	use	of	amphetamine	among	primary	
amphetamine	users	in	recent	years	(ranging	from	52%	to	82%).14	
Until	 recently,	methamphetamine	use	was	 largely	 confined	 to	 the	Czech	Republic	 and	Slovakia	but	 some	countries	 in	
Northern	Europe	have	begun	to	report	the	increased	presence	of	methamphetamine	on	their	markets.15	Use	of	amphet-
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Germany: ats seizures, 2003-2009
Source: UNODC ARQ/DELTA
Germany: seized ats laboratories, 2003-2009
Source: UNODC ARQ/DELTA
Germany: number of drug users who came to the attention of the police for the first time 2000-2009


























































































































































2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Amphetamines Ecstasy Heroin Cocaine
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manufacture.	 The	 following	 sections	 focus	on	 selected	 European	 countries	 and	 examine	 the	 latest	ATS	 trends	by	 sub	
region.














mately	 64%	of	 amphetamines	 seized	 in	 2009	were	 confiscated	 in	 the	 provinces	 of	 Saxony	 and	Bavaria,	with	 smaller	
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netherlands: seizures of ats, 2003-2009*
*No data was reported for 2009 and therefore 2008 data was used.  
Source: UNODC/ARQ DELTA
Two	 illicit	 conversion	 laboratories	 of	 BMK	 from	a-phenyl-




drug	 are	mainly	 in	 powder	 form.	 Seizures	 have	 strongly	
fluctuated	 since	 2003.	 Despite	 the	 decline	 in	 seizures	 in	
2008,	 police	 reports	 indicate	 that	 the	 ATS	 laboratories	
detected	that	year	(principally	in	the	west	and	south	of	the	
country)	were	bigger	and	more	large-scale	than	before.	










sold	 as	 ecstasy	 containing	 only	MDMA-like	 substances	
decreased	(to	71%	in	2008),	while	the	proportion	of	ecstasy	
pills	 containing	 miscellaneous	 substances	 increased	 to	
24	 Europol,	2011b.
25	 Netherlands,	2010.
netherlands: seized ats laboratories, 2003-2009*
* No data was reported to UNODC for 2009. however, the Centre of 
Expertise on Synthetic Drugs and Precursors reports 24 seizures of 
manufacturing locations for synthetic drugs in 2009 (Netherlands, 
2011). 
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submitted	 to	UNODC	 since	 2003,	 though	 some	 small-scale	manufacture	 of	 amphetamine	 is	 said	 to	 take	 place	 in	 the	
UK.30	
Annual	prevalence	rates	of	ATS	in	the	UK	remain	relatively	high,	roughly	double	the	European	average	in	2009.	However,	




























netherlands: content of pills sold as ecstasy based on laboratory analyses, 2006-2010    
2006 2007 2008 2009 2010*
Number of pills analysed 2,523 2,319 2,183 2,181 1,186
Only MDMA-like substances 83.2% 84.6% 70.5% 70.8% 82.3%
(Meth)amphetamine 1.8% 0.7% 1.1% 4.9% 3.0%
MDMA-like substances and (meth)amphetamine 2.2% 1.3% 1.4% 1.3% 1.3%
Others** 4.5% 3.8% 7.4% 1.4% 1.4%
Miscellaneous*** 8.3% 9.6% 17.7% 21.7% 11.9%
* Data for 2010 are from January-June.
** Category ‘Others’ may include samples with MDMA and for example, caffeine and other pharmacologically active non-scheduled substances.
*** In 2009, the category ‘Miscellaneous’ consisted mainly of mCPP (11.6%) and mephedrone (7.4%).  
Source: Netherlands, 2011
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in	2009	 to	342.	Further	decreases	are	 reported	 for	2010.	
Most	methamphetamine	is	manufactured	for	domestic	use,	
smaller	quantities	are	trafficked	to	neighbouring	countries	
such	 as	 Germany	 and	 Slovakia.38	 The	main	method	 of	
sourcing	precursors	 for	 illicit	methamphetamine	manufac-
ture	 currently	 appears	 to	 be	 extraction	 of	 ephedrine	 and	
pseudoephedrine	 from	over-the-counter	medical	 prepara-





of	 crystalline	methamphetamine	 trafficking	 and	 use	 in	
Europe.39




england and Wales: annual prevalence of ats among 
the general population*, 2003/04-2009/10
*Aged 16 to 59 years. 
Source: home Office, 2010
england and Wales: mean percentage purity of  
certain drugs seized by police, 2003-2008*
*From 2008 data have been provided from Forensic Science Service 
(FSS) and LGC Forensics. Previous data were from FSS only. 
**mg of MDMA base per pill. 



























































































































































West anD centraL europe / CZECh REPUBLIC / SWEDEN / NORWAy
The	Czech	Republic	currently	has	the	highest	annual	preva-
lence	 rate	 for	 both	 amphetamines	 (1.7%)	 and	 ecstasy	





toring	Centre	 for	Drugs	 and	Drug	Addiction	 and	 Europol	
have	 suggested	 possible	 diffusion	 of	methamphetamine	







mine	 in	 2009.	 This	 reflects	 the	 increasing	 availability	 of	
methamphetamine	on	 the	 illicit	 drugs	market	 in	 Sweden.	
Recent	 research	 in	 the	 country	 finds	 that	methampheta-
mine	use	is	increasing	and	is	prevalent	in	most	of	the	coun-
try.	 As	 there	 is	 no	 illicit	 ATS	manufacture	 in	 the	 country,	
amphetamines	 are	 thought	 to	 be	 smuggled	 into	 Sweden	












distinguish	 between	 them.43	Most	 amphetamines	 on	 the	
Norwegian	market	originate	from	illicit	 laboratories	 in	the	
Netherlands,	Russian	Federation,	Poland	and	Lithuania.	The	




were	 dismantled)	 and	 authorities	 estimate	 that	manufac-
ture,	if	any	exists,	is	small-scale.
From	2006	to	2009,	Norway	recorded	the	largest	seizures	
of	methamphetamine	 in	 Europe,	 and	 apart	 from	a	dip	 in	







czech republic: seized methamphetamine  
laboratories, 2003-2009
Source: UNODC/ARQ DELTA 
sweden: seizures of ats, 2003-2009
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with	which	the	drug	is	being	trafficked	to	the	country.	Sei-
zures	 of	methamphetamine	 surpassed	 those	 of	 ampheta-
mine	 for	 the	 first	 time	 in	2009,	accounting	 for	 a	 total	of	
51%	of	ATS	seized	that	year.	For	the	first	time,	two	seizures	
of	 crystalline	methamphetamine	 chloride	were	made	 in	
2009.	Both	 seizures	 (6	 and	7.7	grams	 respectively)	 had	a	
purity	of	almost	100	per	cent.45
Toxicological	 data	 from	 the	 National	 Institute	 of	 Public	
Health	also	provide	evidence	of	the	increasing	presence	of	
methamphetamine	in	Norway.	In	2009,	methamphetamine	
was	 the	 second	most	 commonly	 found	 substance	 after	
alcohol	in	blood	samples	from	drivers	suspected	of	driving	


















countries	of	origin	 for	amphetamine	 in	2009.	Poland	dismantled	eight	amphetamine	 laboratories	 in	2009	 (the	 lowest	
number	of	laboratories	reported	in	ten	years),	and	identified	Germany,	Scandinavia	and	the	United	Kingdom	as	the	main	
destinations	for	amphetamine	manufactured	in	Poland.	













































































































poland: seized amphetamine laboratories, 2003-2009
Source: UNODC ARQ/DELTA
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markets	 in	 other	 European	 countries.	 Ecstasy	 shipments	
transit	the	country	and	are	trafficked	eastwards	to	destina-
tions	such	as	Belarus	and	the	Russian	Federation.	
Lithuanian	 organized	 crime	groups	 are	 believed	 to	 play	 a	
significant	role	 in	the	supply	and	trafficking	of	ATS	to	the	
Russian	 Federation,	 Belarus,	 Scandinavia	 and	 the	 Baltic	








Lithuania: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA





































































































































































































  eastern anD soutH-east europe / BULGARIA
Amphetamines	and	ecstasy	use	are	reportedly	on	the	rise.	The	annual	prevalence	rate	of	ecstasy	is	estimated	at	1%	(up	






















been	 reported	 since	 2001	 but	 in	 2010,	 two	mobile	methamphetamine	 laboratories	were	 seized.	Organized	 criminal	
groups	operate	in	Bulgaria,	manufacturing,	tabletting	and	trafficking	amphetamine	out	of	the	country	to	the	Near	and	
Middle	East.	Apart	from	Bulgarian	citizens,	national	authorities	have	identified	the	involvement	of	nationals	from	Lebanon,	


























2011 GLoBaL ATS ASSESSMENT
Bulgaria: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
turkey: seizures of captagon pills, 2005-2009
Source: UNODC ARQ/DELTA; Turkey, 2011
turkey: captagon trafficking routes 
Source: Turkey, 2011 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations. 
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precursor chemical seizures & trafficking
ephedrine and pseudoephedrine
While	seizures	of	ephedrine	and	pseudoephedrine	remain	low	in	Europe,	these	precursor	chemicals	are	being	transshipped	
through	 Europe	with	 increasing	 frequency;	 often	 via	Amsterdam,	 Brussels,	 Frankfurt,	 London	 and	 Paris,	 destined	 for	
Mexico.	 In	2006-07	 the	Netherlands	 reported	an	attempted	diversion	of	more	 than	200	 tons	of	ephedrine	and	pseu-
doephedrine	to	Europol,	while	German	authorities	confiscated	14.5	tons	of	ephedrine	and	more	than	1.6	million	pseu-
doephedrine	pills	 in	2008.76	In	2010,	the	International	Narcotics	Control	Board	warned	that	pills	containing	ephedrine	
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europe: seizures of ephedrine (kg), 2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of p-2-p (litres), 2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of substances required for the  
manufacture of amphetamines-group substances, 
2005-2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 
Convention as reported to the International Narcotics Control Board, 
2005-2009
europe: seizures of substances required for the  
manufacture of ecstasy-group substances, 2005-2009
Source: INCB – Seizures of substances in Tables I and II of the 1988 

















































































































































about	 one	 third	 of	 that	 year’s	 global	 seizures	 –	while	 in	August	 2010,	 the	 International	Narcotics	Control	 Board	was	
















































2	 The	seizure	was	made	by	Saudi	Arabian	Customs	at	Dhuba	seaport.	The	drugs	had	been	concealed	on	board	 the	vessel	which	arrived	 from	Egypt	 (WCO,	
2010).	
3	 UNODC,	2010b.	





































































* From 2007 onwards, reported prevalence percentage is based on midpoint of range.  
- Not reported. 
Source: UNODC ARQ/DELTA
africa: ats laboratories, seizures, and annual prevalence rates (2005-2009)
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Trafficking routes of methamphetamine in Africa
Source: UNODC, 2011a 
Note: The boundaries and names shown and the designations used 
on this map do not imply official endorsement or acceptance by the 
United Nations. Lines represent origin and intended destination, not 
necessarily exact route, and include completed or stopped traffick-
ing attempts. Modes of transport include by air, sea, overland, or 
any combination thereof.
Since 2006, fears have been growing that African countries are being used as trans-shipment points for shipments of 
precursor chemicals such as ephedrine and pseudoephedrine, the main chemicals used in the manufacture of ATS such 
as methamphetamine and methcathinone from Asia. The final destination of these chemicals are countries in Central and 
North America, and to a lesser extent, South Africa. 
In 2008, INCB identified Africa as the region with the greatest number of diversions or attempted diversions of ATS pre-
cursor chemicals. Target countries of such diversions in recent years include Botswana, the Democratic Republic of the 
Congo, Ethiopia, Nigeria, Togo, Uganda, the United Republic of Tanzania and Zambia. However, despite the high number 
of attempted diversions of ephedrine and pseudoephedrine to or through Africa, hardly any seizures of these precursors 
have been reported by African countries. Between 2003 and 2008, ephedrine and pseudoephedrine seizures totaled 242 
kg, with South Africa reporting most of these seizures.4 
Since 2008, perhaps due to strengthened controls in certain countries, notably South Africa, and intensified screening by 
authorities of exporting countries of shipments of precursors destined for Africa, the mass smuggling of those substances 
(often in the form of pharmaceutical preparations) through Africa appears to have declined. The absence of attempted 
diversions and seizures of precursors does not necessarily point to a decline in illicit ATS manufacture and trafficking but 
highlights the flexibility with which criminal organizations operate as traffickers continue to search for alternative traffick-
ing routes as well as substitute substances to use in the manufacture of ATS in response to stringent precursor controls 
and law enforcement legislation.
West and Central Africa
Since 2004, criminal organizations have been using West Africa as a transit area for smuggling cocaine from South 
America to Europe and North America, exploiting the region’s many vulnerabilities to their advantage. There is growing 
evidence to suggest that criminal organizations involved in trafficking ATS, particularly methamphetamine, now exploit 
the region in a similar way to cocaine traffickers and look to avoid effective law enforcement to traffic ATS to other parts 
of the world, primarily East Asia. 
4 For instance, between 2000 and 2008, ephedrine and pseudoephedrine seizures in Africa totalled only 242 kg, with South Africa accounting for most of 
those seizures (INCB 2009a).
Seizures of methamphetamine in Japan by African 
country of origin, 2008-2010
Source: JCITAC, 2010
To East Asia via Europe
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ing	 and	 potential	manufacturing	 hub	 for	methampheta-
mine.
Seizure	reports	from	Nigeria	have	strongly	fluctuated	over	
the	 past	 five	 years.	 In	 2007,	Nigeria	 reported	 seizures	 of	










smuggling	 by	Nigerian	 nationals	 intercepted	 by	 Japanese	
custom	officials	has	risen	sharply	since	2009.	From	January	



















In June 2011, the National Drug Law Enforcement 
Agency of Nigeria (NDLEA) seized an illicit meth-
amphetamine laboratory on the outshirts of Lagos 
‒ the first evidence of methamphetamine manu-
facture in Nigeria. The laboratory had an estimated 
capacity of 160 kg - 200 kg of crystalline metham-
phetamine per week.
Source: NDLEA Official Communication, 2011
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south africa: seizures of illicit methamphetamine and 
methcathinone laboratories, 2005-2009
* No laboratory seizures were reported to UNODC in 2008 – however 
seizures of 20 clandestine laboratories manufacturing methampheta-
mine were reported by a government source. 
Source: UNODC/ARQ DELTA
south africa: number of import and export  
notifications of precursor chemicals, 2005-2010
Source: South African Police Service Reports 2006-2010
south africa: methamphetamine as primary  
substance of abuse: Western cape,* 2003-2010
* From 2007, figures are for the whole Western Cape which includes 
Cape Town, Atlantis and Worcester. Up until 2007, figures denote the 






































































































































south africa: drug-related crime rate (per 100,000 
inhabitants), 2005-2010
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metHaQuaLone
South Africa is possibly the world’s largest 
consumer of methaqualone (known as man-
drax). Methaqualone is a sedative-hypnotic 
often smoked in combination with cannabis 
(a form of drug abuse known as the “white 
pipe”) and is smuggled into South Africa from 
China, India transiting countries such as Mo-
zambique, Swaziland and Zimbabwe. Meth-
aqualone is illicitly manufactured in South 
Africa (four laboratories were seized in 2009). 
Illicit methaqualone manufacture reportedly 
also takes place in clandestine laboratories 
in Mozambique, suggesting a desire to avoid 
better policed South African air and sea ports, 
as well as suggesting that the risk of detection 
may well be lower in neighbouring countries.
Source: UNODC ARQ/DELTA






































































north america: ats laboratories, seizures and annual prevalence rates, 2005-2009





































































* From 2007 onwards, reported prevalence percentage is based on midpoint of range. ** Cuarto Informe de Ejecución, 2011; NDIC, 2010b. 
- Not reported. 
Source: UNODC ARQ/DELTA
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canada: seized ats laboratories, 2005-2009






legislation	 and	precursor	 control	measures	 to	 address	 the	
issue.
In	2009,	two	thirds	of	the	 laboratories	seized	were	meth-
amphetamine	 laboratories	 while	 one	 third	was	 for	 the	
manufacture	of	ecstasy.	The	number	of	methamphetamine	
laboratories	 seized	 in	Canada	more	 than	 tripled	 between	
2008	and	2009,	from	7	to	23.	
Increases	 in	 the	manufacture	 of	 ecstasy	 in	 Canada	 have	
coincided	with	 a	 reported	 decline	 in	manufacture	 of	 the	




the	 Canadian	 illicit	 ATS	 drug	 trade	 in	 2009.	 Organized	
crime	 groups	with	 links	 to	 Asia	 (Viet	 Nam),	 South	 Asia	
(India),	and	Eastern	Europe	were	identified	in	2009	as	con-
tinuing	 and	 emerging	 players	 in	 the	 domestic	 synthetic	
drug	landscape.	Mexican	crime	groups	operating	in	Quebec	
were	 also	 identified	 as	 being	 involved	 in	 the	 illegal	 ATS	
drugs	trade	in	Canada.
The	 shortage	 of	 ecstasy	 precursors	 such	 as	 3,4-MDP-2-P	
canada: seizures of ats, 2005-2009
Source: UNODC ARQ/ DELTA
canada: past year ats use, 2004-2009
* No data was provided for crystalline methamphetamine use in the 
2004 survey. 



































































































































nortH america / CANADA
reported	from	Europe	in	2008	and	2009	appears	not	to	have	affected	ecstasy	manufacture	in	Canada.	In	Europe,	effective	














































9	 In	2008	and	2009,	over	13,000	Canadian	nationals	aged	15	and	older	took	part	 in	the	survey	which	was	based	on	the	previously	carried	out	 ‘Canadian	
Addiction	Survey’	(CAS).
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mexico: seizures of methamphetamine laboratories 
and methamphetamine, 2001-2009












































































M ethamphetamine laboratory seizures (right axis)
Methamphetamine seizures (kg, left axis)
mexico: seizures of methamphetamine, 2007-2009
Source: Cuarto Informe de Ejecución, 2011 











































































usa: ats seizures, 2005-2009
Source: UNODC DELTA















































nortH america / MExICO / USA









ened	enforcement	and	precursor	 control	measures	 in	 the	USA.	Strong	 increases	 in	 the	 illicit	manufacture	of	metham-
phetamine	were	reported	from	2008	to	2009.	In	2009,	Mexico	reported	191	methamphetamine	laboratories,	up	from	21	
in	2008.	Most	laboratories	were	discovered	in	the	central	Pacific	region	(in	particular,	the	states	of	Michoacan,	Jalisco	and	












The	 loss	 in	potency	of	this	product	can	be	compensated	by	higher	purity	 levels.	There	have	also	been	 indications	that	
traffickers	have	added	an	additional	purification	step	to	obtain	the	traditional	‘d-methamphetamine.’	





























often	 obtained	 by	 ‘smurfing’14	 and	 several	 states	 in	 the	
USA	have	made	efforts	to	address	the	issue	by	establishing	
control	measures	and	restrictions	on	the	sale	of	pharmaceu-
tical	 preparations	 containing	 these	 precursors.	 Prior	 to	
1976,	prescriptions	were	required	federally	for	all	prepara-
tions	containing	pseudoephedrine.





ods.	 Seizures	of	methamphetamine	 increased	 significantly	





Seizures	 of	 ecstasy	 are	 at	 a	 five-year	 high	 in	 the	USA.	 In	
2009,	3,411	kg	were	reported	seized,	a	15%	increase	com-
pared	to	2008.	With	a	total	of	114	manufacturing	facilities	




usa: methamphetamine seizures along the  
southwest border, in kilograms, 2005-2009
*Partial-year data. 
Source: NDIC, 2010b
usa: annual prevalence of stimulants and metham-












































































usa: methamphetamine-related treatment 
admissions,	2004-2008*
* Treatment Episode Data Set (TEDS) is an admission-based system, 
the admissions do not represent individuals, hence one person 
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south america, central america and caribbean: ats laboratories, seizures and annual prevalence rates 2005-2009






































































*From 2007 onwards, reported prevalence percentage is based on midpoint of range.
- Not reported. 
Source: UNODC ARQ/DELTA
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south america, central america and the caribbean: ats seizures, 2003-2009
Source: UNODC ARQ/DELTA
past 12 months use of any illicit synthetic drug among 
undergraduates in Bolivia, colombia, ecuador and 
peru, 2009
Source: DROSICAN and EU/Andean Community, 2009
south and central america and the caribbean:  
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Lifetime prevalence (% )
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soutH america, centraL america anD tHe cariBBean 





dad	 and	 Tobago	 reported	 a	 perceived	 increase	 in	 ecstasy	










in	 the	 illicit	manufacture	 of	methamphetamine,	 are	 rou-
tinely	seized	in	countries	in	Central	and	South	America.	In	
the	 Caribbean,	 only	 the	 Dominican	 Republic	 has	 been	
reporting	seizures.	Seizures	of	ephedrine,	in	particular,	have	




In	 2009,	Argentinian	 authorities	 seized	 a	 total	 of	 almost	
10.5	mt	of	ephedrine,	accounting	for	about	25%	of	global	
seizures.	 Although	manufacture	 in	 Argentina	 cannot	 be	
ruled	out,	it	is	likely	that	the	large	quantity	of	this	precursor	
chemical	was	 intended	 for	other	destinations,	 possibly	Mexico.1	 Seizures	of	 ephedrine	destined	 for	Mexico	were	 also	
reported	by	Paraguay	and	Chile	in	2009.	Chile	reported	total	ephedrine	seizures	of	almost	1.2	mt	in	2009.2	In	July	2010,	
Guatemalan	police	reportedly	seized	over	half	a	million	capsules	containing	ephedrine	close	to	the	Honduran	border.3
Seizures	of	pseudoephedrine	have	also	been	 increasing	 since	2005,	with	 large	quantities	being	confiscated	 in	Central	
American	countries	in	recent	years.
Between	the	second	half	of	2009	and	the	first	half	of	2010,	authorities	in	El	Salvador	reportedly	confiscated	over	42	mt	
of	 pseudoephedrine.4	 Significant	 seizures	were	 also	 reported	 from	Belize,	Guatemala,	 Honduras	 and	 the	Dominican	
Republic.5	 In	Belize,	pseudoephedrine	 is	 reportedly	 combined	with	 cocaine	and	cannabis	 into	packaged	 shipments	 for	
onward	transit.	In	2009,	423	kg	of	pseudoephedrine	were	seized	in	Belize.	In	addition,	more	than	40	mt	of	phenylacetic	
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south america, central america and the caribbean: 
seizures of pharmaceutical preparations containing 
pseudoephedrine, 2007-2009
Source: OAS/CICAD/MEM, 2011
Brazil: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
Brazil: use of ecstasy-group substances and  
amphetamines-group substances among  
undergraduates, 2010
Source: SENAD, 2010




























































































































































of	 the	 drugs	 from	 Europe	 to	 Brazil.	 In	 2009,	 the	 Federal	
Police	 of	 Brazil	 reportedly	 dismantled	 a	 significant	 drug	












ATS	 seizures	 in	 Argentina	 have	 fluctuated	 over	 the	 past	
seven	 years.	 In	 2009,	 seizures	 of	 ecstasy	 pills	 increased	






date,	but	 in	2009	Chile	 reported	 the	 seizure	of	one	 illicit	
laboratory	 manufacturing	 the	 hallucinogen	 mescaline.	
Ephedrine	has	been	trafficked	from	Chile	to	Mexico	for	the	
illicit	manufacture	of	methamphetamine.	Reported	seizures	
of	 ecstasy	pills	 in	Chile	 showed	a	decline	of	 almost	40%	





argentina: seizures of ats, 2003-2009
Source: UNODC ARQ/DELTA
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south america: seizures of ecstasy, 2005-2009*
* Where years are missing, it indicates that no reports were received.
Source: OAS/CICAD/MEM, 1999-2009
central america and the caribbean: seizures of ecstasy, 2005-2009*

























Venezuela 79,260 7,616 2,097
Uruguay 857 0 23,474 556 0
Suriname 24 3,154 785 0
Peru 158 71 179 1,619 112
Chile 4,153 3,799 2,590
Colombia 8,533 17,752 7,745 3,737 23,477
Brazil 57,015 11,826 205,448 133,013 28,312
Argentina 3,570 23,075 67,755 11,072 136,550

























Jamaica 500 1,023 2,785
Bahamas 5 0 19 160
Barbados 2,445 0
Costa Rica 138 5,968 19,021 346 416
Dominican Republic 280,722 121,882 20,861 17,885 10,116
2005 2006 2007 2008 2009
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colombia
Colombia	 seized	 126,573	 ATS	 pills	 in	 2009,	 including	
23,477	ecstasy	pills.	 In	addition,	a	shipment	of	15	million	








facture	might	 shift	 towards	 countries	 in	Central	America.	
Several	 countries	 in	 Central	 America	 have	 reported	 inci-
dents	related	to	illicit	ATS	manufacture.	Guatemala	reported	
the	 seizure	 of	 one	ATS	 laboratory	 in	 2008	 and	 three	 in	
2009,	as	well	as	the	seizure	of	12	mt	of	pseudoephedrine	
in	 2009.	 In	 2008,	Honduran	 authorities	 dismantled	 some	
establishments	 used	 for	 extracting	 pseudoephedrine.	 In	
Nicaragua,	 police	 discovered	 a	 laboratory	manufacturing	
illicit	synthetic	drugs	 in	February	2010,	and	seized	a	small	
quantity	 of	 amphetamine.10	 Central	 American	 countries	
accounted	for	two	thirds	of	illicit	ATS	laboratories	seized	in	
the	region	in	2009.
Smaller	 quantities	 of	ATS	 seizures	 have	 been	 reported	 by	
several	countries	in	the	region.	In	2009,	small	quantities	of	















































































the	 key	 starting	materials,	 discusses	 current	manufacturing	methods	 and	 the	 available	 end	products	 in	 illicit	markets.	
Specifically,	the	chapter	looks	at	ephedrine	and	pseudoephedrine	as	well	as	1-phenyl-2-propanone	(P-2-P),	phenylacetic	
acid	and	emerging	trends	related	to	these	substances.	With	regard	to	precursors	of	ecstasy-group	substances,	trends	and	
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precursor seizures
Precursor seizure data are typically used to illustrate 
that illicit manufacture is taking place in a given 
country or region. It is, however, important to rec-
ognize that seizure data can only provide a partial 
(and qualitative) picture of precursor availability. 
Diversions and stopped shipments following regula-
tory interventions are not included in the traditional 
seizure statistics; neither are domestic diversions, 
followed by onward smuggling. This applies also to 
diversions of pharmaceutical preparations contain-
ing controlled precursors (e.g. ephedrine and pseu-
doephedrine), including the numerous small-scale 
diversions or purchases of over-the-counter prepara-
tions, which provide the raw material for the thou-
sands of clandestine methamphetamine laboratories 
seized in the USA and Oceania. Finally, substitute 
chemicals and pre-precursors not under interna-
tional control are not widely recorded, although the 
number of reported seizures is on the increase.
In general, precursor seizure successes may be ac-
counted for by better focus and/or capacity of law 
enforcement authorities and better regulatory con-
trol, possibly related to greater awareness of the ATS 
problem as a whole. Varying law enforcement strate-
gies in different countries may also account for differ-
ences in reported precursor seizures and the extent 
of illicit activity.
Precursor seizure statistics therefore tend to show 
more the impact from national and regional ini-
tiatives, major seizures, and the qualitative devel-
opment of local drug markets, versus providing a 
quantitative measure of precursor availability. Some 
recent examples of qualitative changes include:
•• The more frequent use of different forms of con-
trolled precursors in clandestine ATS manufacture, 
including,
– pharmaceutical preparations containing 
ephedrine and pseudoephedrine
– natural raw materials such as safrole-rich oils 
(containing ecstasy-group precursors) 
•• The appearance of a number of substitute chemi-
cals of controlled precursors, including methyl, 
ethyl, isobutyl, amyl esters of phenylacetic acid 
(precursor of P-2-P), and the methyl glycidate de-
rivative of the ecstasy-group precursor 3,4-methyl-
enedioxyphenyl-2-propanone (3,4-MDP-2-P)
•• The impact of chemical controls in an increasing 
number of traditional transit countries is forcing 
the establishment of new trafficking regions that 
are less well prepared (e.g. Africa), as evidenced 
by increasing reports of diversion and smuggling in 
countries of those regions.
Global seizures of methamphetamine precursors, 
2005-2009
Source: INCB, 2009b, 2010b and 2011b
Global seizures of 1-phenyl-2-propanone(p-2-p) 
(Litres) and phenylacetic acid (kg)






















































































Precursors for methamphetamine and amphetamine
Methamphetamine precursors: ephedrine and pseudoephedrine
Ephedrine	and	pseudoephedrine	are	the	main	precursors	for	methamphetamine	and	can	be	converted	to	the	drug	by	a	
number	 of	 relatively	 simple	 reductive	 synthetic	methods.	 Both	 substances,	 in	 their	 bulk	 form,	 are	 under	 international	
control	and	are	also	precursors	for	the	stimulant	methcathinone,	synthesized	through	a	simple	oxidation	process.
Global	seizures	of	ATS	precursors	have	fluctuated	significantly,	continuing	the	trend	seen	from	2001	to	2006.	In	2007,	

































ing	 significant	 seizures.	Belgium	 reported	a	 seizure	of	5,000	 litres	of	P-2-P	 in	2010.	 In	2009,	China	also	 reported	 the	
destruction	of	8.7	mt	of	P-2-P	that	had	been	accumulated	over	a	number	of	years.	
Seizures	of	phenylacetic	acid	have	 increased	over	the	same	period:	 from	159	kg	 in	2007	to	over	41	mt	 in	2009,	with	
Mexico	 (30.6	mt),	China	 (8.5	mt)	and	Serbia	 (1.9	mt)	accounting	 for	most	of	 recent	 seizures.	 Following	strengthened	
controls	by	Mexico	over	phenylacetic	acid	and	its	salts	and	derivatives	in	2010,	seizures	of	esters	of	phenylacetic	acid	have	
been	reported	more	frequently,	including	one	shipment	of	45	mt	of	ethyl	phenyl	acetate	in	Belize.	These	substances	can	
be	 easily	 converted	 to	 phenylacetic	 acid	 and	 as	 such,	 these	 and	other	 possible	 “masked”	precursors	 are	 expected	 to	
appear	more	frequently	 in	 future	seizures.The	 investigation	and	analysis	of	chemicals	seized	during	the	dismantling	of	
illicit	laboratories	provides	a	crucial	early	indicator	into	the	latest	trends	in	illicit	manufacture.
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Global seizures of ecstasy-group precursors,  
2005-2009 
Source: UNODC calculations based on INCB data taken from  
INCB, 2009b, 2010b and 2011b
Precursors for ecstasy group substances: 3,4-MDP-2-P, safrole, isosafrole, piperonal
The	main	 ecstasy-group	 substances	 are	 3,4-methylenedioxymethamphetamine	 (MDMA),	 and	 its	 analogues,	 including	























Global seizures of ats precursors, 2007-2009 
Source: UNODC calculations based on INCB data taken from 







































































Amphetamine precursors (P-2-P, phenylacetic acid)
Methamphetamine precursors (ephedrine,
pesudoephedrine)
























sible	 for	manufacturers	 to	 easily	 adapt	methods	 used	 to	manufacture,	 for	 example,	 amphetamine	 to	make	metham-
phetamine.	













most commonly used manufacturing methods and their yields
enD proDuct
precursor  
(1 KG or 1 Lt.)
syntHesis metHoD (metHoD) practicaL yieLD
Amphetamine P-2-P (lt.) Ammonium formate (Leuckart) 55%
Amphetamine P-2-P (lt.) Formamide (Leuckart) 67%
d,l-Methamphetamine P-2-P (lt.) Formic acid (Leuckart) 60%
d-Methamphetamine Pseudo/ ephedrine (kg) Red phosphorus / iodine 47%
d-Methamphetamine Pseudo/ ephedrine (kg) Red phosphorus / hydriodic acid 54%
d-Methamphetamine Pseudo/ ephedrine (kg) Lithium / ammonia (‘Birch’) 55%
d-Methamphetamine Pseudo/ ephedrine (kg) hypophosphorous acid / iodine 76%
d-Methamphetamine Pseudo/ ephedrine (kg) Thionyl chloride (Emde) 70%
Methcathinone Pseudo/ ephedrine (kg) Potassium permanganate 50%
MDA Sassafras oil* (lt.) hydrogen peroxide/ sodium cyanoborohydride 12%
MDA 3,4-MDP-2-P (lt.) Sodium cyanoborohydride 37%
MDA Piperonal Nitroethane 41%
MDMA Sassafras oil* (lt.) hydrogen peroxide/ aluminium amalgam 31%
MDMA Sassafras oil* (lt.) hydrobromic acid 48%
MDMA 3,4-MDP-2-P (lt.) Formic acid (Leuckart) 66%
MDMA Sassafras oil* (lt.) Methyl nitrite/ aluminium amalgam (Wacker) 68%
MDMA 3,4-MDP-2-P (lt.) Aluminium amalgam (reductive amination) 95%
* at 75% safrole. 
Source: Royal Canadian Mounted Police and health Canada; Suravina, L. G. and Voronenko, L. A. (1994). Forensics Investigation of Narcotic and Drastic 
Substances Obtained from Ephedra Grass Using home Production Methods. Ministry of Justice of the Republic of Kazakhstan, Kazakhs Scientific 
Research Institute; DEA, Methamphetamine Synthesis #7 (1997).
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The	most	common	synthetic	methods	used	for	the	manufacture	of	ATS	are	shown	below.	The	three	most	common	meth-


























Safrole-rich oils are the main raw materials for the manufacture of safrole for commercial purposes. They are 
marketed worldwide in large quantities as starting materials for the fragrance and pesticide industries. 
There are a number of safrole-rich plant species that constitute the starting materials for the extraction of saf-
role; they are found in North America, South America, East Asia and South-East Asia. Safrole can be present in 
their essential oils at concentration levels of more than 90%. 
Safrole-rich oil tree species grow naturally and/or are cultivated for commercial purposes. To produce the oil, the 
trees are typically felled and the oil distilled from the timber, the root and stump. Oil yields from the distillation 
process typically range between 1% and 3.5%. however, many of these operations remain unregulated and as a 
consequence, there are not only concerns from the point of view of diversion into illicit drug manufacture, but 
also concerning environmental aspects, ecology systems and forestry. 
A recent survey in six countries in East and 
South-East Asia found 361 plants that con-
tain essential oils rich in safrole, most of 
which were of the Cinnamomum species. 
Other plant species rich in safrole include 
the North American Sassafras albidum 
(~80% safrole) and the Brazilian Ocotea pre-
tiosa (~80% safrole) and Piper hispidinervum 
(~90% safrole). 
The reported global licit trade of safrole-rich oils for 
2009-2010 was estimated at 101,840 litres.
* Safrole-rich oils are defined as “any mixtures or natural products containing safrole present in such a way that it can be used or recovered by 








detected	 in	2009	 including	9,420	 in	 the	USA	and	191	 in	
Mexico.	Most	of	 the	 laboratories	 in	 the	United	States	are	
small-scale	laboratories,	where	operators	are	noted	to	often	
purchase	 pharmaceutical	 preparations	 containing	 ephe-




routes.	 The	 chemicals	 seized	 included	 over	 30,000	 kg	 of	







suspended	 in	 toluene.	 In	 another	 laboratory	 producing	



























This figure shows the molecular structures of methamphetamine (1), 
amphetamine (2) and their main precursor substances, pseudoephe-
drine (A), ephedrine (B), phenyl-2-propanone (P-2-P)(C) and pheny-
lacetic acid (D). The arrows indicate the flexibility of the ATS 
manufacturing process and illustrate the similarities of the precur-
sors and relative simplicity of the transformations required to con-

























unregulated products sold in ats markets
Several unregulated substances have appeared in established ATS markets at an unprecedented pace, as manu-
facturers and traffickers exploit the lack of controls. These substances often have chemical and/or pharmaco-
logical properties and effects similar to a known illicit substance. As these substances are not controlled by the 
United Nations international drug control treaties, they are marketed as “legal highs”. Substances are frequently 
labelled “plant food”, “bath salts”, “incense” or “scented sachets”. They are often sold in online shops: the EM-
CDDA found that the number of online shops selling such substances increased from 170 to 277 from 2010 to 
2011.
piperazines are often sold on illicit markets as ‘ecstasy’ and they may also be included as adulterants in pills. Pip-
erazines are typically taken orally, but can also be smoked or snorted. The most commonly reported piperazine 
is benzylpiperazine (BZP), others include 1-(3-chlorophenyl)piperazine (mCPP) and 1-(3-trifluoromethyl-phenyl)
piperazine (TFMPP).
Ketamine1 is often sold as ‘ecstasy’ or ‘amphetamine’ in the form of a bottled liquid or as a whitish powder. Its 
use has been reported in Asia, Americas, Europe and Oceania and it is under national control in several countries. 
synthetic cathinones are analogues to, or derivatives of, the internationally controlled substance cathinone, 
one of the psychoactive substances in the khat plant. Some of the most widespread synthetic cathinones are: 
mephedrone, methylenedioxypyrovalerone (MDPV- “bath salt”), methedrone, 4-fluoromethcathinone, 3-fluor-
omethcathinone, methylone. Some of the synthetic cathinones like mephedrone are under national control in 
several countries, particularly in Europe. 
synthetic cannabinoids are typically synthetic cannabinoid receptor agonists that function similar to delta-9-
tetrahydrocannabinol (ThC), the principal psychoactive component in cannabis. In 2008, several synthetic can-
nabinoids were detected in herbal smoking blends (e.g. ‘spice’, ’yucatan fire’) and include homologues of the 
nonclassical cannabinoid CP-47,4972 and the aminoalkylindole JWh-018 [e.g. JWh-122], which are potent can-
nabimimetics. 
Plants with psychoactive properties sold in ATS market include:
Kratom (Mitragyna speciosa) - a plant indigeneous to South-East Asia that contains the alkaloid mitra-
gynine. The most frequent mode of administration is making tea out of the dried leaves. It is a control-
led substance in several Asian and European countries.
Salvia divinorum - a plant which contains the hallucinogen salvinorin A. The substance is administered 































situation	and	received	107	replies	 to	 its	questionnaire	on	drug	abuse	and	106	replies	 to	 its	questionnaire	on	the	 illicit	
supply	of	drugs	relating	to	2009.	The	proportion	of	questionnaires	that	were	returned	by	region	in	2009	and	2010	for	
the	reporting	year	2009	were:	Europe	(80%	demand	and	88%	supply),	Asia	(64%	and	62%),	Americas	(59%	and	53%);	
Africa	 (27%	and	25%)	and	Oceania	 (12%	for	both	demand	and	supply).1	There	are	Member	States	and	regions	 that	






challenges in analysing ats data
seizure data
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diverted	 pharmaceutical	 preparations	 and	other	 chemicals	 not	 under	 international	 control.	 For	 example,	 based	on	 an	
initial	 2007	 snapshot,	 pharmaceutical	 preparations	 accounted	 for	 a	 significant	proportion	of	 seized	pseudoephedrine.	
Additionally,	increased	utilization	of	Pre-Export	Notifications	(PEN)	has	quite	probably	stopped	or	suspended	some	diver-






yields	 for	 pseudoephedrine-based	methamphetamine	 of	 50%,	 and	 38%	 for	 sassafras	 oil-based	MDMA.2	 By	 2006,	
reported	yields	had	increased	substantially	to	71%	and	80%,	respectively.	These	increases	were	likely	due	to	changes	in	
manufacturing	methods,	 greater	 operator	 skills	 and/or	 greater	 laboratory	 sophistication.	Additionally,	 there	 are	 some	
2	 UNODC,	2003.





























































































in	 their	 quality	 and	 timeliness.	 For	 example,	 the	World Drug Report 2008	 reported	amphetamine and ecstasy-group 
prevalence	estimates	 for	166	 countries	 and	 regions,3	with	an	average	estimate	 that	was	3.3	 years	old	at	 the	 time	of	
publication.	In	the	World	Drug	Report	2011	the	number	of	countries	and	regions	has	decreased	to	120,	with	the	data	
being	4.6	years	old	on	average.	While	some	improvements	have	been	seen,	other	regions	still	fall	far	behind.	






countries	where	household	 surveys	or	other	prevalence	estimates	are	outdated,	 lacking	 in	 completeness	or	quality,	or	
simply	do	not	exist.






















































are	 not	 understood	well	 enough	 or	 quickly	 enough	 to	 enable	 the	 design	 of	 the	 required	 strategic	 interventions	 and	


















facture,	 trafficking	 and	 use	 among	 law	 enforcement,	 health	 and	 regulatory	 authorities	 as	well	 as	 the	 general	 public;	
advancing	the	systematic	collection	of	data	on	ATS	use,	the	diversion	of	precursors	and	preparations	containing	ATS	and	
using	the	data	 in	 implementing	appropriate	 responses	 to	 the	problem;	assessing	the	health,	safety	and	environmental	
implications	related	to	illicit	manufacture;	and	developing	and	implementing	measures	to	address	the	demand	and	provide	
treatment	services	for	ATS	users.	
The	 international	community	has	recognized,	most	notably	 in	the	1998	UNGASS	Action Plan on ATS	as	well	as	 in	the	
Political	Declaration	and	Plan	of	Action	on	 International	Cooperation	 towards	an	 Integrated	and	Balanced	Strategy	 to	
Counter	the	World	Drug	Problem	adopted	in	2008,	that	ATS	continue	to	pose	a	serious	and	constantly	evolving	challenge	
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